Description
Release form
Solution for intravenous and intramuscular administration
Packing
5 pcs.
Indications
Conditions requiring short-term relaxation of skeletal muscles, including:
endotracheal intubation before surgical procedures,
reduction of dislocations,
reposition of bone fragments during fractures with the prevention of electrosurgical prophylaxis,
.
Contraindications
hypersensitivity to suxamethonium chloride,
severe hepatic dysfunction,
pulmonary edema,
severe hyperthermia,
malignant hyperthermia (history of hyperplasia or low-grade hyperplasia days),
severe burns,
penetrating eye damage,
neuromuscular transmission disorders,
children under 1 year old,
patients with uremia, especially with high levels of serum potassium.
Special instructions
There is evidence of cases of irreversible cardiac arrest after the use of suxamethonium chloride in children and adolescents who had previously not detected neuromuscular diseases. In view of the danger of side effects, it is recommended to limit the use of suxamethonium chloride even in apparently healthy children and adolescents, except in cases in which immediate intubation or release of the airways in critical situations is required.
LISTENON ®, like all peripheral muscle relaxants, can only be prescribed by doctors who have experience working with artificial respiration devices and have the ability to perform intratracheal intubation and who have ready-to-use artificial respiration devices under positive pressure, as well as devices that provide sufficient oxygen access and carbon dioxide removal.
To prevent pronounced bradycardia, bronchospasm, or other muscarinic-like effects, administration of atropine is recommended before taking LISTENON ®.
Composition of
1 ampoule with 5 ml of isotonic aqueous solution for injection contains suxamethonium chloride 100 mg
Dosage and administration
Intravenously in the form of an infusion, or as an infusion, intramuscularly. For a long drip infusion, 0.1% LISTENON® solution is used.
Dosage depends on the desired degree of muscle relaxation, body weight and individual patient sensitivity.
With the introduction of LISTENON® 0.1 mg / kg, skeletal muscle relaxation is observed without respiratory depression. A dose of 0.2 mg / kg to 1.0 mg / kg leads to complete relaxation of the muscles of the abdominal wall and skeletal muscles and, in the future, to limit or completely stop spontaneous breathing.
If intravenous administration is not possible, up to 2.5 mg / kg of body weight is prescribed intramuscularly, a maximum of 150 mg. The onset of muscle relaxation during intramuscular administration may be slightly delayed.
Use for children only if absolutely necessary (see Special instructions).
Dosage for children is: 1 – 2 mg / kg of body weight intravenously or up to 2.5 mg / kg intramuscularly.
Intravenous drip: depending on the patient s body weight and the desired degree of muscle relaxation, the adult dose is 0.5 mg – 5 mg / min in a 0.1-0.2% solution.
LISTENON® is compatible with 0.9% sodium chloride solution, Ringer’s solution, 5% dextrose solution and 6% dextran solution.
Side effects
allergic reactions,
salivation,
increase in temperature,
decrease in pressure,
cardiac arrest.
Overdose
Symptoms: increased severity of side effects, respiratory arrest.
Treatment: transfusion of whole blood or canned plasma, artificial respiration with intermittent positive pressure. Transfer to double blocking with the subsequent use of neostigmine.
Storage conditions
In a dark place at a temperature of 2 to 8 ° C.
Term hodnosty
3 years
Deystvuyuschee substances
Suksametonyya chloride
Form of Treatment
simply entails dlya inaektsiy and infusing
Nycomed, Norway
